Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2017.0268

REVIEW

Disrupting transcriptional bio-circuits with next-generation drugs: Realistic or elusive approach?

Evangelos Simeonidis, PhD.

Affiliation: Evangelos Simeonidis, (ES), PhD, Institute for Systems Biology, 401 Terry Avenue, North Seattle, WA 98109, USA; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 7, avenue des Hauts-Fourneaux, L-4362 Esch-Sur-Alzette, Luxembourg.

T: +1 (206) 732-2119

E-mail: evangelos.simeonidis@uni.lu

Abstract
In contrast to rapid progress for (HER2)-positive breast cancer with trastuzumab and trastuzumab-emtasine conjugate (T-DM1) agent no targeted drug has been developed for HER2 negative women with breast cancer, yet. Recently, Palbociclib has approved by the FDA for postmenopausal women with estrogen receptor – positive (ER+)/HER2-negative metastatic breast cancer. Future perspective and challenges for this subcategory of patients are discussed.

(Citation: Gastric & Breast Cancer 2017; 12(2): 135-142)

Back

 

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 31 August 2017